- Home
- IBTA vs CLDX Comparison
IBTA vs CLDX Comparison
Compare IBTA & CLDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IBTA
- CLDX
- Stock Information
- Founded
- IBTA 2011
- CLDX N/A
- Country
- IBTA United States
- CLDX United States
- Employees
- IBTA N/A
- CLDX N/A
- Industry
- IBTA
- CLDX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- IBTA
- CLDX Health Care
- Exchange
- IBTA Nasdaq
- CLDX Nasdaq
- Market Cap
- IBTA 892.4M
- CLDX 1.3B
- IPO Year
- IBTA 2024
- CLDX 2008
- Fundamental
- Price
- IBTA $36.75
- CLDX $22.53
- Analyst Decision
- IBTA Buy
- CLDX Buy
- Analyst Count
- IBTA 10
- CLDX 9
- Target Price
- IBTA $74.60
- CLDX $50.00
- AVG Volume (30 Days)
- IBTA 362.7K
- CLDX 1.0M
- Earning Date
- IBTA 08-13-2025
- CLDX 08-07-2025
- Dividend Yield
- IBTA N/A
- CLDX N/A
- EPS Growth
- IBTA 24.66
- CLDX N/A
- EPS
- IBTA 2.03
- CLDX N/A
- Revenue
- IBTA $369,501,000.00
- CLDX $7,559,000.00
- Revenue This Year
- IBTA $6.89
- CLDX N/A
- Revenue Next Year
- IBTA $15.55
- CLDX N/A
- P/E Ratio
- IBTA $18.29
- CLDX N/A
- Revenue Growth
- IBTA 7.20
- CLDX 24.49
- 52 Week Low
- IBTA $31.40
- CLDX $14.40
- 52 Week High
- IBTA $79.80
- CLDX $47.00
- Technical
- Relative Strength Index (RSI)
- IBTA N/A
- CLDX 62.49
- Support Level
- IBTA N/A
- CLDX $22.30
- Resistance Level
- IBTA N/A
- CLDX $23.85
- Average True Range (ATR)
- IBTA 0.00
- CLDX 1.17
- MACD
- IBTA 0.00
- CLDX 0.14
- Stochastic Oscillator
- IBTA 0.00
- CLDX 86.14
About IBTA Ibotta Inc. Class A Common Stock
Ibotta Inc is a performance marketing platform. It allows CPG brands to deliver digital promotions to consumers through a single, convenient network called the Ibotta Performance Network (IPN).
About CLDX Celldex Therapeutics Inc.
Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. It has single operating and reportable segment that operates in the business of development, manufacturing and commercialization of novel therapeutics for human health care.